Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free CMRAW Stock Alerts

Comera Life Sciences (CMRAW) Competitors

Compare

CMRAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Ainos?

Comera Life Sciences (NASDAQ:CMRAW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Ainos N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

In the previous week, Ainos had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for Ainos and 0 mentions for Comera Life Sciences. Ainos' average media sentiment score of 0.93 beat Comera Life Sciences' score of 0.00 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
Comera Life Sciences Neutral
Ainos Positive

Summary

Ainos beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Comera Life Sciences (NASDAQ:CMRAW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Alvotech had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Comera Life Sciences. Alvotech's average media sentiment score of 1.89 beat Comera Life Sciences' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Very Positive
Comera Life Sciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

Alvotech beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Aravive?

Aravive (NASDAQ:ARAV) and Comera Life Sciences (NASDAQ:CMRAW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Comera Life Sciences N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Aravive's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Aravive Neutral
Comera Life Sciences Neutral

Summary

Aravive beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Atlantic Coastal Acquisition Corp. II?

Comera Life Sciences (NASDAQ:CMRAW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Summary

Comera Life Sciences beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.

How does Comera Life Sciences compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Comera Life Sciences (NASDAQ:CMRAW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Biofrontera had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Comera Life Sciences. Biofrontera's average media sentiment score of 1.87 beat Comera Life Sciences' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Very Positive
Comera Life Sciences Neutral

Summary

Biofrontera beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRAW vs. The Competition

Export
MetricComera Life SciencesBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$445.83M$6.52B$12.05B
Dividend YieldN/A3.88%2.67%5.66%
P/E RatioN/A3.1824.0024.42
Price / SalesN/A6,505.70533.77123.88
Price / CashN/A13.1327.4837.92
Price / BookN/A86.9110.556.82
Net IncomeN/A-$96.07M$3.57B$337.56M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2
AIMDW
Ainos
N/A$0.13
-3.8%		N/A+25.5%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.22
+20.5%		N/A-83.2%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-87.6%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRAW) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel